Avicanna Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Avicanna yıllık ortalama 21.7% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 12.9% annual. Gelirler yılda ortalama 66.5% oranında büyüyor .

Anahtar bilgiler

21.7%

Kazanç büyüme oranı

45.3%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	7.3%
Gelir büyüme oranı	66.5%
Özkaynak getirisi	-74.0%
Net Marj	-27.3%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Avicanna nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:0NN Gelir, gider ve kazançlar (CAD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	25	-7	17
30 Jun 24	25	-7	16
31 Mar 24	22	-7	15
31 Dec 23	17	-9	14
30 Sep 23	12	-12	13
30 Jun 23	6	-14	12
31 Mar 23	4	-16	11
31 Dec 22	4	-15	11
30 Sep 22	4	-16	12
30 Jun 22	4	-16	13
31 Mar 22	4	-15	12
31 Dec 21	3	-17	13
30 Sep 21	2	-24	14
30 Jun 21	2	-29	15
31 Mar 21	2	-34	17
31 Dec 20	2	-33	17
30 Sep 20	2	-25	19
30 Jun 20	1	-24	21
31 Mar 20	0	-21	22
31 Dec 19	0	-22	22
30 Sep 19	0	-18	18
30 Jun 19	0	-14	14
31 Mar 19	0	-11	11
31 Dec 18	0	-7	8
30 Sep 18	0	-5	6
31 Dec 17	0	-3	3

Kaliteli Kazançlar: 0NN şu anda kârlı değil.

Büyüyen Kar Marjı: 0NN şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 0NN kârlı değildir, ancak son 5 yılda zararlarını yılda 21.7% oranında azaltmıştır.

Büyüme Hızlandırma: 0NN 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 0NN kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 25.4% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 0NN hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -74% ) sahiptir.

Avicanna Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.016 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.021 loss per share (vs CA$0.021 loss in 2Q 2023)

First quarter 2024 earnings released: CA$0.011 loss per share (vs CA$0.033 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in FY 2022)

Avicanna Inc. to Report Fiscal Year 2023 Results on Apr 01, 2024

Third quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.048 loss in 3Q 2022)

Recent updates

Third quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.016 loss in 3Q 2023)

Avicanna Inc. announced that it has received CAD 0.80001 million in funding

Avicanna Inc. announced that it has received CAD 1.986208 million in funding

Second quarter 2024 earnings released: CA$0.021 loss per share (vs CA$0.021 loss in 2Q 2023)

Avicanna Announces United States Patent and Trademark Office Issuance of Patent SEDDS Technology

Avicanna Inc., Annual General Meeting, Jul 10, 2024

Insider recently bought €169k worth of stock

First quarter 2024 earnings released: CA$0.011 loss per share (vs CA$0.033 loss in 1Q 2023)

Avicanna Inc. Announces Results of Study in Patients with Epidermolysis Bullosa

Avicanna Inc. announced that it has received CAD 2.125584 million in funding

Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study

Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in FY 2022)

Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation

Avicanna Inc. to Report Fiscal Year 2023 Results on Apr 01, 2024

Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox

Avicanna Inc. announced that it has received CAD 0.888128 million in funding

Less than half of directors are independent

Third quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.048 loss in 3Q 2022)

Avicanna Announces Appointment of Paul Fornazzari to Board of Directors

Avicanna Inc. to Report Q3, 2023 Results on Nov 14, 2023

Avicanna Inc. Provides Update on the Successful Launch of MyMedi.ca

Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors

Second quarter 2023 earnings released: CA$0.021 loss per share (vs CA$0.08 loss in 2Q 2022)

Avicanna Inc. announced that it has received CAD 1.455 million in funding

Avicanna Inc. (TSX:AVCN) completed the acquisition of Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc.

Avicanna Inc. (TSX:AVCN) entered into definitive Asset Purchase Agreement to acquire Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc. for CAD 2.6 million.

First quarter 2023 earnings released: CA$0.033 loss per share (vs CA$0.02 loss in 1Q 2022)

Insider recently bought €90k worth of stock

Avicanna LATAM S.A.S. Announces Step Down of Lucas Nosiglia as President, Effective January 31, 2023

Avicanna Inc. announced that it has received CAD 1.769097 million in funding

Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the Rho Phytotm Cbg Transdermal Gel Topical Product

Avicanna Inc. Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market

Insider recently bought €388k worth of stock

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Avicanna Inc. announced that it has received CAD 0.626763 million in funding

Avicanna Files Complete Patent Specifications Relating to A Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Avicanna Introduces a New Medical Cannabis Education Online Portal, "Avicenna Academy" for Health Care Professionals

Assad Kazeminy Retires as Director of Avicanna Inc

Second quarter 2022 earnings released: CA$0.08 loss per share (vs CA$0.067 loss in 2Q 2021)

Avicanna Inc. announced that it has received CAD 2.782302 million in funding

Avicanna Inc., Annual General Meeting, Aug 31, 2022

An unknown buyer acquired 63 percent stake in Sativa Nativa S.A.S. from Avicanna Inc. (TSX:AVCN) for CAD 0.81 million.

Forecast to breakeven in 2024

First quarter 2022 earnings released: CA$0.02 loss per share (vs CA$0.085 loss in 1Q 2021)

Avicanna Inc. Announces Chief Financial Officer Changes

Avicanna Inc. announced that it has received CAD 1.473826 million in funding from Ei.Ventures, Inc.

Full year 2021 earnings released: CA$0.41 loss per share (vs CA$1.12 loss in FY 2020)

Avicanna Inc. announced that it has received CAD 2.523568 million in funding

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin